Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic ...

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in ...

— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic device (CIED) procedures — “Every innovation we ...

A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/. About Elutia ...

Elutia (ELUT) announced the initiation of an EluPro clinical study designed to collect patient outcome data in real-world clinical practice.

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams ...

Elutia Inc. has announced the launch of a clinical study for EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs).

A live and archived webcast of the fireside chat will be available in the“Investors” section of the Elutia website at . Elutia develops and commercializes drug-eluting biomatrix products to ...